Savara Inc. announced that its product, Molgramostim, successfully treats Autoimmune Pulmonary Alveolar Proteinosis, based on trial results published in the New England Journal of Medicine.
1 report, 1 independent
Updated Aug 21
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Savara Inc. announced that its product, Molgramostim, successfully treats Autoimmune Pulmonary Alveolar Proteinosis, based on trial results published in the New England Journal of Medicine.
Who's involved
What this event is mainly aboutSavara (Denmark)Bruce C Trapnell
Keep exploring
The entities involved
-
Savara (Denmark)
company in Hørsholm, Denmark
Nothing else this week.
Coverage
Newest first; wire copies grouped- Business WireNew England Journal of Medicine (NEJM) to Publish Results From Savara’s Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) -- In the Largest Clinica